Cancer Research

A new study by Qatar Foundation researchers from the Qatar Genome Research Consortium and Weill Cornell Medicine-Qatar has reported the first landscape of cancer germline variation – known as inherited cancer – in the Middle East.  The study  The study, led by Dr. Lotfi Chouchane from Weill Cornell Medicine-Qatar (WCM-Q), has been published online in […]

In this white paper, brought to you by BioRad, hear from leading industry experts in the emerging field of cancer vaccines. The experts discuss: Challenges related to antigen and adjuvant selection Vaccine design Immune response improvement Future treatment options Download the white paper here.

Sonia Marsilio is an Associate Product Manager at Enzo. She explains how research tools enable scientists to accelerate immunotherapy.  The growing, continuously evolving arsenal of cancer immunotherapies has changed the treatment landscape of many tumours. Dominating the space are the CAR T cell therapies, with CD19, BCMA, and CD22 as the top targets for haematological malignancies and undisclosed tumour-associated antigen […]

Phesi has released the results of its global analysis of all clinical trials conducted in 2021, which shows that breast cancer was the most studied disease area, followed by Covid-19. Overall, oncology dominated the top five, which also included non-small cell lung cancer, solid tumours and multiple myeloma (Figure 1).   Findings  Within breast cancer clinical […]

2022’s World Cancer Day theme is “Close the Care Gap”1 and is focused on raising awareness of the cancer care equity gap that affects almost everyone, in high as well as low- and middle-income countries, and costs lives. DDW’s Megan Thomas comments on the crisis as well as initiatives that are working to close this gap.  World Cancer Day is a […]

Novartis UK has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given a positive scientific opinion for the investigational treatment asciminib to be made available to appropriate patients under the UK Early Access to Medicines Scheme (EAMS).1  What does this mean?  The decision means that adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia […]

Otsuka Pharmaceutical and Astex Pharmaceuticals’ oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukaemia (AML)1 has been granted orphan-drug designation (ODD) by the European Commission (EC).  What is ALM?  AML is the most common form of acute leukaemia in adults2. Within Europe, there is an increase in the incidence […]

Since the turn of the century, when the term “personalised medicine” was first coined, the use of molecular diagnostic (or biomarker) testing in clinical trials has continued to grow in terms of complexity and importance. These tests have undergone a period of rapid development and growth in the last decade, with the implementation of new high complexity tests […]

Not only is there is a severe lack of effective T-cell lymphoma (TCL) treatments, according to GlobalData, but the data and analytics company does not expect any significant solutions to appear in the next decade.  Context  According to GlobalData, one key unmet need is found in the cutaneous TCL (CTCL) subtype. Early-stage CTCL has a favourable prognosis and is […]

Researchers at the Francis Crick Institute, UCL, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London have developed a computer model to analyse how the way in which tumours grow affects their genetic makeup. Using this new model, they have identified links between tumour growth and shape, and how quickly a […]